X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare IPCA Labs with Novartis - Equitymaster
  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

IPCA LABS vs NOVARTIS - Comparison Results

IPCA LABS    Change

Ipca Laboratories is an integrated pharmaceutical company with presence in intermediates, APIs and formulations. The company has a strong focus on exports, catering to the US, Europe and the semi-regulated markets of the CIS, Africa and Asia. The com... More

NOVARTIS 
   Change

Novartis is a 76% subsidiary of Novartis AG - Switzerland and has a countrywide presence in the healthcare business. While pharmaceuticals contributes 70% to total revenues (FY10), generics (6%), consumer healthcare i.e. OTC (14%) and animal health (... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    IPCA LABS NOVARTIS IPCA LABS/
NOVARTIS
 
P/E (TTM) x 44.4 360.9 12.3% View Chart
P/BV x 3.4 17.8 19.2% View Chart
Dividend Yield % 0.2 1.6 9.3%  

Financials

 IPCA LABS   NOVARTIS
EQUITY SHARE DATA
    IPCA LABS
Mar-17
NOVARTIS
Mar-16
IPCA LABS/
NOVARTIS
5-Yr Chart
Click to enlarge
High Rs643982 65.5%   
Low Rs503556 90.4%   
Sales per share (Unadj.) Rs254.4252.9 100.6%  
Earnings per share (Unadj.) Rs16.162.1 25.9%  
Cash flow per share (Unadj.) Rs29.863.3 47.0%  
Dividends per share (Unadj.) Rs1.0010.00 10.0%  
Dividend yield (eoy) %0.21.3 13.4%  
Book value per share (Unadj.) Rs194.6363.6 53.5%  
Shares outstanding (eoy) m126.2031.96 394.9%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x2.33.0 74.1%   
Avg P/E ratio x35.712.4 288.1%  
P/CF ratio (eoy) x19.212.2 158.3%  
Price / Book Value ratio x2.92.1 139.2%  
Dividend payout %6.216.1 38.7%   
Avg Mkt Cap Rs m72,30024,580 294.1%   
No. of employees `00013.30.8 1,769.0%   
Total wages/salary Rs m6,9601,801 386.4%   
Avg. sales/employee Rs Th2,413.510,748.9 22.5%   
Avg. wages/employee Rs Th523.22,395.2 21.8%   
Avg. net profit/employee Rs Th152.42,641.1 5.8%   
INCOME DATA
Net Sales Rs m32,1068,083 397.2%  
Other income Rs m226829 27.2%   
Total revenues Rs m32,3328,913 362.8%   
Gross profit Rs m4,448234 1,899.1%  
Depreciation Rs m1,73037 4,712.5%   
Interest Rs m2412 13,377.8%   
Profit before tax Rs m2,7031,025 263.7%   
Minority Interest Rs m00-   
Prior Period Items Rs m017 0.0%   
Extraordinary Inc (Exp) Rs m01,696 0.0%   
Tax Rs m675752 89.8%   
Profit after tax Rs m2,0281,986 102.1%  
Gross profit margin %13.92.9 478.1%  
Effective tax rate %25.073.4 34.0%   
Net profit margin %6.324.6 25.7%  
BALANCE SHEET DATA
Current assets Rs m17,34012,678 136.8%   
Current liabilities Rs m9,5592,433 392.9%   
Net working cap to sales %24.2126.7 19.1%  
Current ratio x1.85.2 34.8%  
Inventory Days Days10033 306.8%  
Debtors Days Days5722 252.9%  
Net fixed assets Rs m20,77969 30,027.6%   
Share capital Rs m252160 157.9%   
"Free" reserves Rs m24,49911,460 213.8%   
Net worth Rs m24,55311,621 211.3%   
Long term debt Rs m3,5170-   
Total assets Rs m39,59514,400 275.0%  
Interest coverage x12.2570.5 2.1%   
Debt to equity ratio x0.10-  
Sales to assets ratio x0.80.6 144.4%   
Return on assets %5.713.8 41.5%  
Return on equity %8.317.1 48.3%  
Return on capital %10.523.6 44.5%  
Exports to sales %48.60.7 6,531.4%   
Imports to sales %14.218.6 76.6%   
Exports (fob) Rs m15,61760 25,942.5%   
Imports (cif) Rs m4,5711,503 304.2%   
Fx inflow Rs m15,617186 8,382.9%   
Fx outflow Rs m5,8281,821 320.1%   
Net fx Rs m9,790-1,635 -598.9%   
CASH FLOW
From Operations Rs m2,7642,531 109.2%  
From Investments Rs m-1,432-8,270 17.3%  
From Financial Activity Rs m-1,591-386 412.6%  
Net Cashflow Rs m-259-6,125 4.2%  

Share Holding

Indian Promoters % 45.9 0.0 -  
Foreign collaborators % 0.0 75.0 -  
Indian inst/Mut Fund % 11.4 2.0 570.0%  
FIIs % 25.3 1.6 1,581.3%  
ADR/GDR % 0.0 0.0 -  
Free float % 17.4 21.5 80.9%  
Shareholders   36,892 41,647 88.6%  
Pledged promoter(s) holding % 2.1 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare IPCA LABS With:   PLETHICO PHARMA  BIOCON LTD  J.B.CHEMICALS  ALKEM LABORATORIES  AJANTA PHARMA  

Compare IPCA LABS With:   MYLAN (US)  ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  TEVA PHARMA (Israel)  



Today's Market

Indian Indices End Day Flat; Oil and Gas Stocks Lead Losses(Closing)

After opening the day in red, share markets in India witnessed negative trading activity throughout the day and ended the day on a weak note.

Related Views on News

Aster DM Healthcare (IPO)

Feb 10, 2018

Should you subscribe to the IPO of Aster DM Healthcare Ltd?

Dr Reddy's: Milestone Payment Drives Sales (Quarterly Results Update - Detailed)

Feb 9, 2018

US business was hit by pricing pressure although there was growth sequentially led by new product launches.

Lupin: US market Declines Due to Higher Base Effect of FY17 (Quarterly Results Update - Detailed)

Feb 9, 2018

Price erosion in generic US drugs continues but seems to be bottoming out.

Biocon: US Pricing Pressure Takes Toll (Quarterly Results Update - Detailed)

Feb 2, 2018

Pricing pressure in the US and costs of the Malaysian facility hit Biocon's profits in the third quarter.

Shalby Ltd. (IPO)

Dec 2, 2017

Should you subscribe to the IPO of Shalby Ltd?

More Views on News

Most Popular

The Foundation for Sensex 100,000 is Laid(The 5 Minute Wrapup)

Feb 17, 2018

Top three reasons for Tanushree's presentation at Equitymaster Conference to be centered around a possible 30% correction.

The Era of Easy Money is Coming to an End. What Happens Now?(Vivek Kaul's Diary)

Feb 9, 2018

The easy money policy of the Federal Reserve of the United States, which drove up stock markets all over the world, is ending, with the Federal Reserve looking to shrink its balance sheet.

The Markets Want Your Money. Don't Give It to Them.(Smart Contrarian)

Feb 9, 2018

MFs are having a gala time taking money from over-eager investors and funneling it into equities. Smart investors, though, know better than to do that.

The Big Gamble(The Honest Truth)

Feb 15, 2018

Once you accept the fact that elections are round the corner and that this budget is geared to reach a 40% target, everything makes sense.

NPAs Set to Rise Further with New RBI Rules(Chart Of The Day)

Feb 15, 2018

The RBI overhauls bad loan framework. Banks may come under additional pressure due to rising NPAs and increased provisioning.

More

Small Investments
BIG Returns

Zero To Millions Guide 2018
Get our special report, Zero To Millions
(2018 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

IPCA LABS SHARE PRICE


Feb 22, 2018 (Close)

TRACK IPCA LABS

  • Track your investment in IPCA LABS with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

IPCA LABS 8-QTR ANALYSIS

COMPARE IPCA LABS WITH

MARKET STATS